LifeStance Health Appoints Three New Directors, One Resigns
LFST has more than doubled off its 52-week low of $3.74.
Summary
LifeStance Health Group announced a significant change to its board of directors with the resignation of one member and the immediate appointment of three new independent directors.
Key Events · Executive and Board Changes · LFST
-
Director Resignation
Jeffrey Rhodes resigned from the Board and all committees, effective July 2, 2026. The company explicitly stated his resignation was not due to any disagreement.
-
Three New Director Appointments
Thurman Justice, Lori Goltermann, and Safwan Shabab were appointed as directors, filling vacancies. They will serve on various committees, including audit, compensation, and nominating/governance.
-
Equity Awards for New Directors
Mr. Justice and Ms. Goltermann each received an initial award of 35,492 restricted stock units (RSUs) that will vest based on time and performance, subject to their continued service.
Analysis · LFST · Industrial Applications And Services
The company is refreshing its board with three new appointments following a non-contentious resignation. This change in board composition could influence future strategic direction and governance, bringing new expertise to key committees.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFST was trading at $10.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $3.74 to $11.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.